TLX591 is an investigational anti-PSMA 1 radio-antibody-drug conjugate (rADC) therapy being developed for the treatment of mCRPC, differentiated by a short two-week dosing regimen. Reported median ...
When the Rural Adams Development Corp. recently celebrated its 25th anniversary, there was an interesting point made by its members. Since 1992, RADC, which consists of officials from seven rural ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results